Ground-breaking study to restore vision uses CRISPR technologyMay 24, 2021
Mass Eye and Ear is co-leading a new, revolutionary clinical trial that uses CRISPR gene editing to correct a genetic mutation that leads to a form of blindness caused by Leber congenital amaurosis, an inherited retinal disorder. Clinical trial participant Michael Kalberer is the second person in the world to receive this therapy.
Michael details his reasons for being a pioneer in this new research on the Focus blog. His doctors, Eric Pierce, MD, PhD, and Jason Comander, MD, PhD, of the Ocular Genomics Institute and the Inherited Retinal Disorders Service, joined him in a Mass Eye and Ear video about the groundbreaking study. Dr. Pierce and Michael also spoke with NPR about their experience